These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21569199)

  • 1. COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy.
    Belshaw Z; Constantio-Casas F; Brearley MJ; Dunning MD; Holmes MA; Dobson JM
    Vet Comp Oncol; 2011 Jun; 9(2):141-8. PubMed ID: 21569199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cyclooxygenase-2 in canine nasal carcinomas.
    Impellizeri JA; Esplin DG
    Vet J; 2008 Jun; 176(3):408-10. PubMed ID: 17517527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
    Queiroga FL; Pires I; Lobo L; Lopes CS
    Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
    Heller DA; Clifford CA; Goldschmidt MH; Holt DE; Shofer FS; Smith A; Sorenmo KU
    Vet Pathol; 2005 Nov; 42(6):776-80. PubMed ID: 16301573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of hypofractionated radiotherapy for nasal tumours in 38 dogs (2005-2008).
    Fujiwara A; Kobayashi T; Kazato Y; Yayoshi N; Fujita M
    J Small Anim Pract; 2013 Feb; 54(2):80-6. PubMed ID: 23373834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
    Knottenbelt C; Mellor D; Nixon C; Thompson H; Argyle DJ
    J Small Anim Pract; 2006 Apr; 47(4):196-200. PubMed ID: 16573762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas.
    Borzacchiello G; Russo V; Russo M
    J Vet Med A Physiol Pathol Clin Med; 2007 Jun; 54(5):247-9. PubMed ID: 17523957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993-2003).
    Rassnick KM; Goldkamp CE; Erb HN; Scrivani PV; Njaa BL; Gieger TL; Turek MM; McNiel EA; Proulx DR; Chun R; Mauldin GE; Phillips BS; Kristal O
    J Am Vet Med Assoc; 2006 Aug; 229(3):401-6. PubMed ID: 16881833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas.
    Borzacchiello G; Paciello O; Papparella S
    J Comp Pathol; 2004 Jul; 131(1):70-6. PubMed ID: 15144801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival.
    Lavalle GE; Bertagnolli AC; Tavares WL; Cassali GD
    Vet Pathol; 2009 Nov; 46(6):1275-80. PubMed ID: 19605908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cyclooxygenase-2 in canine epithelial nasal tumors.
    Kleiter M; Malarkey DE; Ruslander DE; Thrall DE
    Vet Radiol Ultrasound; 2004; 45(3):255-60. PubMed ID: 15200266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reirradiation of recurrent canine nasal tumors.
    Bommarito DA; Kent MS; Selting KA; Henry CJ; Lattimer JC
    Vet Radiol Ultrasound; 2011; 52(2):207-12. PubMed ID: 21388476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of specific magnetic resonance imaging features in canine nasal tumours treated by radiotherapy.
    Agthe P; Caine AR; Gear RN; Dobson JM; Richardson KJ; Herrtage ME
    J Small Anim Pract; 2009 Dec; 50(12):641-8. PubMed ID: 19954440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy.
    Fu DR; Kadosawa T
    J Vet Med Sci; 2022 Sep; 84(9):1237-1243. PubMed ID: 35851267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in canine nasal carcinomas.
    Paciello O; Borzacchiello G; Varricchio E; Papparella S
    J Vet Med A Physiol Pathol Clin Med; 2007 Oct; 54(8):406-10. PubMed ID: 17877580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Cox-1 and Cox-2 in canine mammary tumours.
    Queiroga FL; Alves A; Pires I; Lopes C
    J Comp Pathol; 2007; 136(2-3):177-85. PubMed ID: 17416236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and survival following radiation therapy for canine nasal tumors: A single-institution retrospective study of 166 cases.
    Mizuno R; Mori T
    Open Vet J; 2024 Jul; 14(7):1538-1552. PubMed ID: 39175976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation of clinical signs in 48 dogs with nasal carcinomas treated with coarse-fraction radiation therapy.
    Gieger T; Rassnick K; Siegel S; Proulx D; Bergman P; Anderson C; LaDue T; Smith A; Northrup N; Roberts R
    J Am Anim Hosp Assoc; 2008; 44(3):116-23. PubMed ID: 18451069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis and treatment for 98 patients with carcinoma of nasal cavity].
    Hu WH; Xie FY; Chen DZ; Wu Y; Jiao JJ; Peng WJ; Yan C; Fang SH
    Ai Zheng; 2004 Nov; 23(11 Suppl):1542-5. PubMed ID: 15566676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megavoltage irradiation of neoplasms of the nasal and paranasal cavities in 77 dogs.
    Théon AP; Madewell BR; Harb MF; Dungworth DL
    J Am Vet Med Assoc; 1993 May; 202(9):1469-75. PubMed ID: 8496103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.